Medicare is preparing to offer weight loss coverage for GLP-1 drugs like Wegovy and Zepbound starting in July 2026, with a patient copay of $50. However, the Centers for Medicare and Medicaid Services (CMS) has not released data estimating the total cost to taxpayers for this new benefit. The lack of financial transparency comes despite the fact that taxpayers will fund the majority of the expenses for these high-cost therapies.